Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety and Tolerability of SR419 in Healthy Subjects
NCT05012761Phase 1Completed
- Sponsor
- Shanghai SIMRD Biotechnology Co., Ltd.
- Start
- Aug 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Peripheral neuropathic pain comparing SR419 with Placebo (2 arms). Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 4 more. Started Aug 2021; status: completed.
02
Drugs
sr419
03
Conditions
Peripheral neuropathic pain
Beyond the preview
Go deeper on NCT05012761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05012761.